Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura.
FACT-Cog
Fatigue
HADS
HRQoL
TTP
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
17
12
2023
accepted:
20
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
26
4
2024
Statut:
aheadofprint
Résumé
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially life-threatening disorder. Treatment advances have lowered morbidity rates, but past acute events can still cause long-term consequences, reducing health-related quality of life (HRQoL) and determining cognitive impairment, anxiety, and depression. We aimed to investigate these aspects and the role of caplacizumab and rituximab: 39 patients were evaluated using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), the FACIT-Fatigue, the Hospital Anxiety and Depression Scale, and the Functional Assessment in Cancer Therapy-Cognitive Function questionnaires. The median age at study inclusion was 50 years (IQR 38-60), and the median follow-up from diagnosis was 97 months (IQR 14-182); 82% of patients were female, and 36% had one or more recurrences. Caplacizumab was administered in 16 patients (41%), as well as rituximab. ITTP patients reported lower physical and mental HRQoL scores than the general population. No differences in physical or mental domains were observed between patients treated or not with caplacizumab, while those who received rituximab reported lower scores in mental health. Neurological impairment at diagnosis correlated with worse fatigue. The majority of patients (72%) reported anxiety or depression (82%). ITTP had a significant impact on the long-term cognitive function, fatigue, depression, and anxiety levels of patients, with a negative effect on their HRQoL. Our findings underscore the need to pay special attention to patients' long-term physical and mental health, regardless of the medical treatments received.
Identifiants
pubmed: 38671298
doi: 10.1007/s00277-024-05771-3
pii: 10.1007/s00277-024-05771-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Kremer Hovinga JA, Coppo P, Lämmle B et al (2017) Thrombotic thrombocytopenic purpura. Nat Rev Dis Primer 3:17020. https://doi.org/10.1038/nrdp.2017.20
doi: 10.1038/nrdp.2017.20
Falter T, Böschen S, Schepers M et al (2021) Influence of personality, resilience and life conditions on depression and anxiety in 104 patients having survived Acute Autoimmune thrombotic Thrombocytopenic Purpura. J Clin Med 10:365. https://doi.org/10.3390/jcm10020365
doi: 10.3390/jcm10020365
pubmed: 33477992
pmcid: 7835833
Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 380:335–346. https://doi.org/10.1056/NEJMoa1806311
doi: 10.1056/NEJMoa1806311
pubmed: 30625070
Peyvandi F, Callewaert F (2016) Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374:2497–2498. https://doi.org/10.1056/NEJMc1603180
doi: 10.1056/NEJMc1603180
pubmed: 27332911
Sargentini-Maier ML, De Decker P, Tersteeg C et al (2019) Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura. Expert Rev Clin Pharmacol 12:537–545. https://doi.org/10.1080/17512433.2019.1607293
doi: 10.1080/17512433.2019.1607293
pubmed: 30977686
Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486–2495. https://doi.org/10.1111/jth.15006
doi: 10.1111/jth.15006
pubmed: 32914582
pmcid: 8146131
Scully M, Cohen H, Cavenagh J et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451–461. https://doi.org/10.1111/j.1365-2141.2006.06448.x
doi: 10.1111/j.1365-2141.2006.06448.x
pubmed: 17233847
Coppo P, Bubenheim M, Azoulay E et al (2021) A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137:733–742. https://doi.org/10.1182/blood.2020008021
doi: 10.1182/blood.2020008021
pubmed: 33150928
pmcid: 7986049
Deford CC, Reese JA, Schwartz LH et al (2013) Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 122:2023–2029. https://doi.org/10.1182/blood-2013-04-496752
doi: 10.1182/blood-2013-04-496752
pubmed: 23838348
pmcid: 3778546
Selvakumar S, Liu A, Chaturvedi S (2023) Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship. Front Med 10. https://doi.org/10.3389/fmed.2023.1137019
McHorney CA, Ware JE, Raczek AE (1993) The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263. https://doi.org/10.1097/00005650-199303000-00006
doi: 10.1097/00005650-199303000-00006
pubmed: 8450681
Ware JE, New England Medical Center Hospital, Health Institute (1994) SF-36 physical and mental health summary scales: a user’s manual. Health Institute, New England Medical Center, Boston
Apolone G, Cifani S, Liberati M (1997) Questionario sullo stato di salute SF-36®. Traduzione e validazione della versione italiana: risultati del progetto IQOLA. Metodologia e Didattica Clinica. 86–94
Colangelo KJ, Pope JE, Peschken C (2009) The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 36:2231–2237. https://doi.org/10.3899/jrheum.090193
doi: 10.3899/jrheum.090193
pubmed: 19723907
Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 37:23–31. https://doi.org/10.1177/009286150303700105
doi: 10.1177/009286150303700105
Cella D, Lai J, Chang C-H et al (2002) Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94:528–538. https://doi.org/10.1002/cncr.10245
doi: 10.1002/cncr.10245
pubmed: 11900238
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
doi: 10.1111/j.1600-0447.1983.tb09716.x
pubmed: 6880820
Wagner L, Sabatino T, Cella D et al (2005) Cognitive function during cancer treatment: the FACT-Cog study. J Robert H Lurie Compr Cancer Cent Northwest Univ 10:10–15
Wagner L, Sweet J, Butt Z et al Cognitive function during cancer treatment. J Support Oncol 7:W32–W39
Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J DIJ Drug Inf Assoc 37:23–31. https://doi.org/10.1177/009286150303700105
doi: 10.1177/009286150303700105
Taylor R (1990) Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonogr 6:35–39. https://doi.org/10.1177/875647939000600106
doi: 10.1177/875647939000600106
Chander DP, Loch MM, Cataland SR, George JN (2019) Caplacizumab therapy without plasma exchange for acquired thrombotic Thrombocytopenic Purpura. N Engl J Med 381:92–94. https://doi.org/10.1056/NEJMc1905426
doi: 10.1056/NEJMc1905426
pubmed: 31269374
Junior ASF, Lessa MPM, Kaplan S et al (2023) Patient-reported outcome measures in patients with Thrombotic Thrombocytopenic Purpura: a systematic review of the literature. J Clin Med 12. https://doi.org/10.3390/jcm12155155
Lewis QF, Lanneau MS, Mathias SD et al (2009) Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfus (Paris) 49:118–124. https://doi.org/10.1111/j.1537-2995.2008.01938.x
doi: 10.1111/j.1537-2995.2008.01938.x
Riva S, Mancini I, Maino A et al (2020) Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura. Haematologica 105:1957–1962. https://doi.org/10.3324/haematol.2019.226423
doi: 10.3324/haematol.2019.226423
pubmed: 31558667
pmcid: 7327631
Holmes S, Podger L, Bottomley C et al (2021) Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom. Hematol Amst Neth 26:465–472. https://doi.org/10.1080/16078454.2021.1945236
doi: 10.1080/16078454.2021.1945236
Cataland SR, Scully MA, Paskavitz J et al (2011) Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 86:87–89. https://doi.org/10.1002/ajh.21881
doi: 10.1002/ajh.21881
pubmed: 20981675
Han B, Page EE, Stewart LM et al (2015) Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 90:709–714. https://doi.org/10.1002/ajh.24060
doi: 10.1002/ajh.24060
pubmed: 25975932
pmcid: 4509840
Kennedy AS, Lewis QF, Scott JG et al (2009) Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfus (Paris) 49:1092–1101. https://doi.org/10.1111/j.1537-2995.2009.02101.x
doi: 10.1111/j.1537-2995.2009.02101.x
Chaturvedi S, Yu J, Brown J et al (2023) Silent cerebral infarction during immune TTP remission - prevalence, predictors, and impact on cognition. Blood J Blood 2023019663. https://doi.org/10.1182/blood.2023019663
Scully M, De La Rubia J, Pavenski K et al (2022) Long-term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study. J Thromb Haemost 20:2810–2822. https://doi.org/10.1111/jth.15892
doi: 10.1111/jth.15892
pubmed: 36138517
pmcid: 9827931
Owattanapanich W, Wongprasert C, Rotchanapanya W et al (2019) Comparison of the long-term remission of rituximab and conventional treatment for Acquired Thrombotic Thrombocytopenic Purpura: a systematic review and meta-analysis. Clin Appl Thromb off J Int Acad Clin Appl Thromb 25:1076029618825309. https://doi.org/10.1177/1076029618825309
doi: 10.1177/1076029618825309
Arnold DM, Heddle NM, Carruthers J et al (2012) A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 119:1356–1362. https://doi.org/10.1182/blood-2011-08-374777
doi: 10.1182/blood-2011-08-374777
pubmed: 22223819
Chaturvedi S, Oluwole O, Cataland S, McCrae KR (2017) Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thromb Res 151:51–56. https://doi.org/10.1016/j.thromres.2017.01.003
doi: 10.1016/j.thromres.2017.01.003
pubmed: 28113083